Improving outcomes in early prostate cancer: Part II - Neoadjuvant treatment

BJU International

Volumn 98, Issue 4, 2006, Pages 731-734

  Mazhar, Danish ^a   Ngan, Sarah ^a   Waxman, Jonathan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; KETOCONAZOLE; PACLITAXEL; VINBLASTINE; WARFARIN;

ADJUVANT CHEMOTHERAPY; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; FOLLOW UP; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33748546625     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06370.x     Document Type: Short Survey

References (27)

1. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996; 14 (Suppl. 2): 22-31
2. Sullivan L, Gleave M, Goldenberg L et al. Long-term neoadjuvant hormonal therapy prior to radical prostatectomy in localized prostate cancer. J Urol 1994; 151: 435A
3. Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997; 157: 1727-30
4. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2b:NxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 424-8
5. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-6
6. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3N0M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (Suppl. 3): 65-69
7. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706-13
8. Van Popel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormone therapy before radical prostatectomy decrease the number of positive margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995; 154: 429-34
9. Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 2016-9
10. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999; 162: 2024-8
11. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol 1996; 14 (Suppl. 2): 39-47
12. Klotz L, Gleave M, Goldenberg SL. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol 2000; 4: 233-7
13. Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 2003; 62 (Suppl. 1): 46-54
14. Green N, Bodner H, Broth E et al. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 1984; 10: 971-6
15. Pilepich MV, Krall JM, Sause WT et al. Prognostic factors in carcinoma of the prostate - analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 339-49
16. Pilepich MV, Buzydlowski JW, John MJ, Rubin P, McGowan DG, Marcial VA. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 1995; 32: 175-80
17. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
18. Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-52
19. Roach M 3rd, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11
20. Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Onc 2000; 18: 1050-7
21. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 281-5
22. El-Rayes BF, Hussain M, Smith D et al. Neoadjuvant docetaxel and estramustine in patients with high risk/locally advanced prostate cancer. Proc Am Soc Clin Oncol 2002; 21: 774
23. Oh WK, George DJ, Kaufman DS et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001; 28 (Suppl. 4): 40-4
24. Garzotto M, Higano CS, Lowe BA et al. Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: a phase I trial. Proc Am Soc Clin Oncol 2002; 21: 2434 (A)
25. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 709-13
26. Zelefsky MJ, Kelly WK, Scher HI et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 2000; 18: 1936-41
27. Ben-Josef E, Porter AT, Han S et al. Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int J Radiat Oncol Biol Phys 2001; 49: 699-703